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Plateletpheresis is a method used to remove platelet from the body either from random
volunteer donors, patient’s family members or HLA matched donors. A cross sectional
study was carried out on 59 plateletpheresis donors aged between 18 and 55 years at
National Blood Center (NBC), Kuala Lumpur. We compared the blood parameters before
and after plateletpheresis and we found that the platelet count, FVIII, ﬁbrinogen and
thrombophilia markers anti-thrombin (AT), protein C and protein S were signiﬁcantly
reduced (p < 0.05) with prolonged PT and APTT. There were signiﬁcant changes in blood
coagulation parameters but it is within acceptable range.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction used to remove platelet from the body either from randomPlatelet can be prepared or collected from whole blood
after several stages of processing or through the apheresis
(plateletpheresis) using cell separators. Apheresis is a tech-
nique performed on donors or patients where by a partic-
ular component of the blood is separated ex vivo and the
remainder of the blood is returned to the donor or patients
[1]. This technology is based on either ﬁltration or centrif-
ugal systems with combination of either continuous- or
intermittent-ﬂow technology [2]. The American Associa-
tion of Blood Banking deﬁned plateletpheresis as a methodvolunteer donors, patient’s family members or HLA
matched donor [3]. This technique is usually used for
donation and therapeutic purposes.
Rate of complications of apheresis varies from 0.89% to
4.8% [4,5]. It has been reported that apheresis procedures
had common complications related to vascular accesses
such as haematoma, venous inﬁltration and venous sclero-
sis or thrombosis [6]. Fatalities due to complications in
apheresis are approximately 0.003–0.02% or less than 1
every 10,000 procedures. Among the potential causes of
fatalities includes cardiac arythmia, adult respiratory dis-
tress syndrome, venous thrombosis and haemorrhagic
events [7,8]. A study on 195.372 donor apheresis proce-
dures reported 9.6% cases developed complications of
which included 5.2% donor related problems, 4% machine
and harness problems and 0.4% due to operator errors
[9]. American Red Cross also reported that in 2006, from
449, 594 plateletpheresis performed about 1/10.000 may
develop minor and major adverse reaction.
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cation system with series of enzymes in which a few initi-
ation substances activated by proteolysis of a cascade of
circulating precursor proteins to generate the thrombin
and converts soluble plasma ﬁbrinogen into ﬁbrin. Effects
of the plateletpheresis can be seen when there are the
changes on the coagulation and thrombophilia markers
after the procedure. Venous thrombosis will develop when
there is a vessel wall damage, abnormal blood ﬂow and
presence of local activation of coagulation. The thrombi
are made up of red blood cells with few platelets which
are trapped in an extensive ﬁbrin mesh. The risks of throm-
boembolism in the general population include increasing
age, medical illness, surgery, immobilization, venous stasis
or sedentary lifestyle, cigarette smoking, pregnancy, use of
oral contraceptives, intensive physical exertion and hyper-
coagulable states [10]. An increase in factor VIII and non-O
blood group are also recognized as risk factors for develop-
ment venous thromboembolism [7].
Most of the studies being done on plateletpheresis usu-
ally focused on the platelet function and the haemostasis
[11,12]. The aim of this study is to determine the effects
of platelet and blood coagulation parameters in healthy
donors after plateletpheresis.
2. Materials and methods
2.1. Patients and study design
This is a cross sectional study conducted from1st January
2009 and 31st December 2009 at National Blood Centre
(NBC), Kuala Lumpur. A total of 59 healthy donors consist
of 57 men and 2 women with mean age of 41.8 years were
selected fromplateletpheresis donor registration. All donors
between 18 and 55 years with last donation more than two
weeks and met the National Blood Centre eligibility criteria
for plateletpheresis donation were selected for this study.
Donors thatwere less than18 years andmore than55 years,
a smoker or were on any medical treatment 7 days prior to
the procedure were excluded in this study. Blood samples
were collected from donors before and after apheresis pro-
cedure. Informed consent was obtained from all donors.
2.2. Plateletpheresis procedure
Apheresis was performed using Spectra LRS (COBE BCT,
Lakewood, CO), Trima (Gambro BCT, Lakewood, CO),Table 1
Platelet and coagulation parameters before and after platelet apheresis.
Parameters Before plateletpheresis
Mean ± SD Range
Platelet (109/L) 294.19 ± 63.28 176.00–455.00
PT (s) 9.15 ± 0.22 9.00–10.47
APTT (s) 28.97 ± 2.89 22.00–34.70
Factor VIII (%) 116.10 ± 27.70 43.52–219.50
Fibrinogen (mg/dl) 295.08 ± 56.43 129.50–437.30
Anti-thrombin (%) 91.68 ± 12.10 65.10–127.00
Protein C (%) 109.30 ± 18.57 76.30–158.00
Protein S (%) 98.19 ± 16.12 61.73–148.82
Paired t-test: p-value is signiﬁcant when p < 0.05.AMICUS (Baxter Fenwal Division, Deerﬁeld, IL) and MCS+
(Haemonetic Corp, Braintree, MA). Acid-citrate-dextrose
formula A (ACD-A) was used as anticoagulant during pro-
cedures according to the manufacture’s recommendations.2.3. Coagulation parameters
Beckman Coulter used to measure platelet count. ACL
Advance System was used for measurements of prothrom-
bin time (PT), activated partial thromboplastin time
(APTT), factor VIII (FVIII) and ﬁbrinogen. Protein C and
anti-thrombin (AT) was measured using ACL Elite Pro Sys-
tem. Plasma levels of protein S were determined by stan-
dard ELISA.2.4. Statistics
The result was analyzed using SPSS version 12.0. Coag-
ulation and thrombophilia parameters were expressed as
mean ± standard deviation (SD). Comparison between be-
fore and after plateletpheresis were analyzed using a
paired t-test and level of signiﬁcant was set at p < 0.05.
This research was approved by the Advance Medical
and Dental Institute (AMDI) and the Medical Research &
Ethics Committee (MREC), Ministry Of Health, Malaysia
(P09-388).3. Results
Coagulation and thrombophilia parameters before and
after plateletpheresis showed in Table 1. The time taken
for PT and APTT immediately after plateletpheresis was
prolonged in the procedure. There was signiﬁcant reduc-
tion of platelet count among plateletpheresis donors from
294.2  109/L to 226.3  109/L (p < 0.05). For procoagu-
lants factors, factor VIII and ﬁbrinogen as well as thrombo-
philia markers that were anti-thrombin, protein C and
protein S also showed signiﬁcant reduced in the values.
However, the overall changes were still within the normal
limit.4. Discussion
Apheresis is a relatively safe procedure that is com-
monly used today for donation and therapeutic purposesAfter plateletpheresis p-Value
Mean ± SD Range
226.25 ± 63.28 126.00–414.00 0.01
9.27 ± 0.31 9.40–11.10 0.01
29.77 ± 2.81 24.10–35.50 0.01
96.08 ± 25.38 50.00–197.60 0.01
247.24 ± 42.22 174.60–354.30 0.01
78.14 ± 10.86 55.90–107.00 0.01
95.61 ± 16.38 67.50–144.00 0.01
84.84 ± 10.16 64.00–110.40 0.01
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before and after plateletpheresis in healthy donors.
From this study, we found that regular plateletpheresis
donor develop sustained decreases in platelet count. These
ﬁndings have also been reported by other researchers.
[6,13–15]. It was found that the donors should be screened
with at least complete blood count before the procedure to
ensure that the platelet does not fall below the normal lim-
it. This is similar to the ﬁndings of Strauss et al. [16]. There
was signiﬁcant reduction of platelet count among platelet-
pheresis donors, perhaps beside collection of platelets; it
might also due to adhesion of platelet to tubing or centri-
fuge bowl. About 25–50% of circulating platelets might
be lost during single plateletpheresis but this is usually
normalized by the spleen, therefore signiﬁcant thrombocy-
topenia is not observed in plateletpheresis donors [17].
Hence, the clinical ﬁndings of thrombocytopenia are unu-
sual. The reduction in platelet count after plateletpheresis
is shown to cause activation of thrombopoiesis to replenish
the platelet in the peripheral blood. The activation of the
thrombopoiesis will induce temporary increase in serum
thrombopoietin level after platelet collection [18].
The prothrombin time (PT) and activated partial throm-
bin time (APTT) was signiﬁcantly prolonged after platelet-
pheresis but they were still within the normal range. There
was prolonged PT/APTT after apheresis procedure, proba-
bly due to citrate from ACD-A solution. However it does
not lead to systemic anticoagulation since it has a short
in vivo half-life. Beyan et al. [14] studied effect of cell sep-
arator on coagulation in plateletpheresis donors. They
compared the values obtained before and they found pro-
longed in PT and APTT. However, some ﬁnding reported
signiﬁcant prolonged in PT and unaffected APTT after pla-
teletapheresis [19].
In this study, the comparison before and after apheresis
coagulation parameters revealed no change that could lead
to thrombosis. The mechanism of thrombosis after plate-
letpheresis is not known but some authors have postulated
that there are changes associated with reduction in anti-
thrombin, protein C and protein S [20,21], induction of
coagulation activation [22], platelet activation, aggregation
and formation of microparticle [23] following automated
apheresis leading to hypercoagulable state. Another possi-
ble mechanism promoting hypercoagulable state is
through extracorporeal circulation. Adsorption of clotting
factors, platelet adhesion, aggregation, and adherence of
white blood cells and red blood cells to the surfaces of
the tubes for blood circulation in the blood cell separator
can also lead to hypercoagulable state [22,24].
A signiﬁcant decrease of plasma ﬁbrinogen, factor VIII
and anticoagulant proteins: protein C, protein S and anti-
thrombin was demonstrated in our study after plateletphe-
resis but they are still within normal level. Therefore, we
believe that decrease in these levels would not lead to
hemostatic problems. In few articles, statistic showed sig-
niﬁcant reduction in plasma ﬁbrinogen and factor VIII after
plateletpheresis in healthy donor [6,25].
This study showed signiﬁcant changes in blood coagula-
tion parameters, however changes were within normal
range. Reduction in blood coagulation parameters are com-
pensated by humoral mechanism. With new technology ofcell separator, the procedure will be terminated when
there is technical or mechanical errors hence risk of hyper-
coagulable state from extracorporal hemostasis can be re-
duced therefore reduce the risk of thrombosis. In
conclusion, plateletpheresis is a safe procedure for healthy
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